OSE IMMUNO (OSE.PA) Stock Price, Forecast & Analysis
Europe - EPA:OSE - FR0012127173 - Common Stock
OSE.PA Key Statistics, Chart & Performance
The current stock price of OSE.PA is 5.333 EUR. In the past month the price decreased by -11.04%. In the past year, price decreased by -38.81%.
OSE.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 75.04 | 49.58B | ||
| 1AE.DE | ARGENX SE | 74.3 | 49.08B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.24B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.56B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.95B | ||
| GLPG.AS | GALAPAGOS NV | 23.96 | 1.77B | ||
| 5CV.DE | CUREVAC NV | 5.2 | 1.02B | ||
| NANO.PA | NANOBIOTIX | N/A | 892.47M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| IVA.PA | INVENTIVA SA | N/A | 504.67M | ||
| FYB.DE | FORMYCON AG | N/A | 416.13M | ||
| ALCLS.PA | CELLECTIS | N/A | 391.77M |
Related stock screener links
About OSE.PA
Company Profile
OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire and currently employs 68 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
Company Info
OSE IMMUNO
22, boulevard Benoni Goullin
Nantes PAYS DE LA LOIRE FR
Employees: 52
Phone: 33228291010
OSE IMMUNO / OSE.PA FAQ
What does OSE do?
OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire and currently employs 68 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
What is the current price of OSE stock?
The current stock price of OSE.PA is 5.333 EUR. The price decreased by -1.97% in the last trading session.
Does OSE stock pay dividends?
OSE.PA does not pay a dividend.
How is the ChartMill rating for OSE IMMUNO?
OSE.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for OSE IMMUNO?
OSE IMMUNO (OSE.PA) has a market capitalization of 119.78M EUR. This makes OSE.PA a Micro Cap stock.
OSE.PA Technical Analysis
OSE.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OSE.PA. While OSE.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
OSE.PA Financial Highlights
Over the last trailing twelve months OSE.PA reported a non-GAAP Earnings per Share(EPS) of -1.59. The EPS decreased by -191.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.44% | ||
| ROE | -68.84% | ||
| Debt/Equity | 0.64 |
OSE.PA Forecast & Estimates
8 analysts have analysed OSE.PA and the average price target is 15.61 EUR. This implies a price increase of 192.63% is expected in the next year compared to the current price of 5.333.
For the next year, analysts expect an EPS growth of -98.83% and a revenue growth -42.08% for OSE.PA